Time filter

Source Type

Benedek Lazar E.,Clinical Hematology and Bone Marrow Transplantation Unit | Beata Kopeczi J.,Clinical Hematology and Bone Marrow Transplantation Unit | Beata Tunyogi A.,Clinical Hematology and Bone Marrow Transplantation Unit | Kakucs E.,Clinical Hematology and Bone Marrow Transplantation Unit | And 4 more authors.
Romanian Journal of Morphology and Embryology | Year: 2013

We present the possibilities of diagnosis correlating the pathological, immunophenotyping and clinical aspects of a rare case of T-cell lymphoma in a 23-year-old patient with leukemic transformation. In our consideration, it is very important to describe this case because in the literature there are very few cases presented and the treatment of this type of lymphoma does not present optimal results, the evolution of the patients being from three months to two years. The treatment modality that gives the possibility to prolong survival and cure is hematopoietic stem cell transplantation.


Szanto A.,University of Medicine and Pharmacy of Targu Mures | Pap Z.,University of Medicine and Pharmacy of Targu Mures | Denes L.,University of Medicine and Pharmacy of Targu Mures | Lazar E.B.,University of Medicine and Pharmacy of Targu Mures | And 5 more authors.
Romanian Journal of Morphology and Embryology | Year: 2015

The Philadelphia chromosome and the resulting BCR-ABL fusion gene represent the hallmark event in chronic myeloid leukemia (CML) and their discoveries radically changed the management of these patients. Currently Wilms tumor 1 gene (WT1) is intensively investigated as high WT1 expression levels have been demonstrated in case of multiple solid tumors and malignant hematological syndromes (acute myeloid and lymphoid leukemia, myelodysplastic syndromes and chronic myeloid leukemia). The aim of our study was to investigate the WT1 expression in CML patients and its possible contribution to disease evolution. Patients and Methods: In the Laboratory of Molecular Biology, University of Medicine and Pharmacy of Tirgu Mures, Romania, we regularly determined the M-BCR-ABL and WT1 expression levels by RQ-PCR (real-time quantitative polymerase chain reaction) testing in case of 19 CML patients: six patients monitorized from the diagnosis and 13 patients first tested during therapy. Results: Eight CML (four advanced stage and four CP) patients showed high WT1 expression level, and in case of 11 patients the WT1 expression levels were undetectable or lower than 0.02%. The only significant difference between the high and low WT1 expression groups was represented by the clinical stage. In the majority of pretreated patients (10 out of 13 patients), the WT1 expression levels were low or undetectable. Conclusions: High WT1 expression in CML patients is detected especially in the advanced stages of the disease. Efficient Imatinib therapy may contribute to low WT1 levels in CP patients. © 2015, Editura Academiei Romane. All rights reserved.

Loading Clinical Hematology and Bone Marrow Transplantation Unit collaborators
Loading Clinical Hematology and Bone Marrow Transplantation Unit collaborators